198 related articles for article (PubMed ID: 20814199)
21. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways.
Bao Y; Jia RH; Yuan J; Li J
Pharmacology; 2007; 80(1):57-64. PubMed ID: 17534120
[TBL] [Abstract][Full Text] [Related]
22. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
[TBL] [Abstract][Full Text] [Related]
23. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression.
Zheng M; Ye S; Zhai Z; Chen Y; Li X; Yang G; Fan A; Wang Y
J Diabetes Complications; 2009; 23(2):124-9. PubMed ID: 18413206
[TBL] [Abstract][Full Text] [Related]
24. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
[TBL] [Abstract][Full Text] [Related]
25. Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing.
Westerweel PE; den Ouden K; Nguyen TQ; Goldschmeding R; Joles JA; Verhaar MC
Am J Physiol Renal Physiol; 2008 Feb; 294(2):F379-84. PubMed ID: 18077601
[TBL] [Abstract][Full Text] [Related]
26. Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.
Efrati S; Berman S; Chachashvili A; Cohen N; Siman-Tov Y; Averbukh Z; Weissgarten J
Nephrology (Carlton); 2009 Apr; 14(2):189-97. PubMed ID: 19143945
[TBL] [Abstract][Full Text] [Related]
27. Novel biphenyl compound, VMNS2e, ameliorates streptozotocin-induced diabetic nephropathy in rats.
Kurundkar SB; Sachan N; Kodam KM; Kulkarni VM; Bodhankar SL; D'Souza S; Vanage G; Ghole VS
J Diabetes; 2010 Dec; 2(4):282-9. PubMed ID: 20923502
[TBL] [Abstract][Full Text] [Related]
28. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Liu DS; Liu WJ; Chen L; Ou XM; Wang T; Feng YL; Zhang SF; Xu D; Chen YJ; Wen FQ
Toxicology; 2009 Jun; 260(1-3):112-9. PubMed ID: 19464576
[TBL] [Abstract][Full Text] [Related]
29. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy?
Zheng F; Guan Y
Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308
[TBL] [Abstract][Full Text] [Related]
30. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
[TBL] [Abstract][Full Text] [Related]
31. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
[TBL] [Abstract][Full Text] [Related]
32. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
Liu IM; Tzeng TF; Liou SS; Chang CJ
J Ethnopharmacol; 2009 Jul; 124(2):211-8. PubMed ID: 19397971
[TBL] [Abstract][Full Text] [Related]
33. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.
Sánchez-Hidalgo M; Martín AR; Villegas I; Alarcón De La Lastra C
Biochem Pharmacol; 2005 Jun; 69(12):1733-44. PubMed ID: 15876425
[TBL] [Abstract][Full Text] [Related]
35. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Wang G; Wei J; Guan Y; Jin N; Mao J; Wang X
Metabolism; 2005 May; 54(5):590-7. PubMed ID: 15877288
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
37. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
[TBL] [Abstract][Full Text] [Related]
38. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
Zhang H; Saha J; Byun J; Schin M; Lorenz M; Kennedy RT; Kretzler M; Feldman EL; Pennathur S; Brosius FC
Am J Physiol Renal Physiol; 2008 Oct; 295(4):F1071-81. PubMed ID: 18667486
[TBL] [Abstract][Full Text] [Related]
39. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone attenuates oxyhemoglobin-induced Toll-like receptor 4 expression in vascular smooth muscle cells.
Wu Y; Zhao XD; Zhuang Z; Xue YJ; Cheng HL; Yin HX; Shi JX
Brain Res; 2010 Mar; 1322():102-8. PubMed ID: 20132800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
